Brainsway Ltd - ADR
BWAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$237.16M
Close$
$3.53
70.1% downside
Current Fair Value
70.1% downsideOvervalued by 70.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $237.16 Million |
|---|---|
| Enterprise Value | $192.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.4 |
| Beta | 0.15 |
| Outstanding Shares | 20,064,705 |
Return
| Return on Equity | 12.76% |
|---|---|
| Return on Assets | 8.28% |
| Return on Invested Capital | 5.09% |
Valuation & Multiples
| P/E Ratio | 47.67 |
|---|---|
| PEG | 144.77 |
| Price to Sales | 3.94 |
| Price to Book Ratio | 2.96 |
| Enterprise Value to Revenue | 2.96 |
| Enterprise Value to EBIT | 38.01 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$16.54 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.12
Average shareholder expectationRevenue Estimate
$17.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 11,000▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.86%▼ 4.52% |
|---|---|
| Total Invested | $176.89M▲ 13.66% |
| Investors Holding | 58▲ 2.00% |
ESG Score
No data
About Brainsway Ltd.
129 employees
CEO: Christopher von Jako Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...